Executive saw sharp downturn in U.S. salesATL president and COO David Perozek is leaving the company effectiveSept. 1, the Bothell, WA, ultrasound vendor announced last week.Perozek's duties as president will be assumed by chairman andCEO Dennis
ATL president and COO David Perozek is leaving the company effectiveSept. 1, the Bothell, WA, ultrasound vendor announced last week.Perozek's duties as president will be assumed by chairman andCEO Dennis Fill until a replacement is found.
ATL said Perozek is resigning for personal reasons and to pursueother interests. He has not joined another company and will continueto be affiliated with ATL in a consulting role through 1996, thecompany said.
Perozek was hired by ATL in 1992 after leaving the medicalproducts group of cardiac ultrasound vendor Hewlett-Packard (SCAN5/20/92). He had served as general manager of the group and supervisedthe company's integration of Apollo Computer, a workstation manufacturerHP acquired.
Perozek saw ATL through a period of great change. Sales inthe U.S. ultrasound industry fell sharply shortly after he joinedthe company. ATL posted revenues in 1993 of $304.5 million, down6.3%, with a net loss of $5.1 million. The company was forcedto restructure operations in mid-1993 and released 11% of itsworldwide work force (SCAN 9/8/93).
Despite the downturn, ATL maintained its activity in the market,both in product development and on a corporate level. The companyintroduced its Extended Signal Processing (ESP) upgrade for theUltramark 9 HDI scanner in 1993 as well as Doppler Power Imaging,its approach to amplitude-based color Doppler that was later upgradedand renamed Color Power Angio.
Last year, ATL acquired cardiac ultrasound developer Interspec,absorbing that company's product line and moving its operationsto Bothell. ATL had revenues of $366.2 million in 1994 with anet loss of $20.2 million. Those figures include the revenue contributionfrom Interspec as well as nonrecurring charges relating to itsacquisition of Interspec and the closure of its Ambler, PA, headquarters.
ATL also introduced the HDI 3000 in 1994 as its new premiumultrasound platform (SCAN 10/26/94). The scanner has been wellreceived by the market and has helped put the company on the roadto profitability. ATL's revenues for the first quarter (end-March)were up 5.6% to $94.4 million, and the firm would have reportednet income of $926,000 were it not for one-time charges of $2.5million relating to the Interspec consolidation.
Perozek's abilities served ATL well throughout this period,Fill said.
"Dave, in these three years, has played a strong rolein the strategic development of the company and in product development,"Fill said. "He made some strong contributions to ATL, particularlyin the areas where his skill sets are good, in the technologyarea and in the area of operations generally."
ATL has restructured its management organization in responseto Perozek's departure. Jacques Souquet, senior vice presidentfor product generation, and Donald Blem, senior vice presidentfor operations, who once reported to Perozek, will now reportdirectly to Fill. Two other senior vice presidents, Harvey Gillisand Castor Diaz, already report to Fill.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.